David gained his PhD in chemistry from Bristol University. From 1990, he worked at AEA Technology, initially studying nuclear accident aerosol behaviour, then developing new techniques for generating aerosol-based advanced materials. In 1997, David joined Bath University to manage industry-funded inhaler development programmes. In 1999, this group became the drug delivery company Vectura, where David was Head of Pulmonary Research, and was responsible for devising the PowderHale formulation technologies. David was co-chair of the annual “Drug Delivery to the Lung” international conference series for over 10 years, and recognised for developing its current format. In 2007, David moved to Monash, with specific research interests in particle engineering, drug delivery and particle surface modification. He led the creation of a $3.5m Centre of Innovation with GSK: a new model for future industry-university collaborations. David has authored over 35 patent applications and has over 70 peer reviewed publications, and 100 conference papers.